Phio Pharmaceuticals
1500 West Park Drive
Suite 210
Westborough
Massachusetts
01581
United States
Tel: 508-767-3861
Fax: 508-767-3862
Website: https://phiopharma.com/
440 articles about Phio Pharmaceuticals
-
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
3/6/2024
Phio Pharmaceuticals Corp. announced that the United States Patent and Trademark Office has granted patent application 17/150,614 for two of its INTASYL Compounds, RXI-185 and RXI-231.
-
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
1/31/2024
Phio Pharmaceuticals Corp. today announced that new preclinical data demonstrating the potential of INTASYL self-delivering siRNA targeting Cbl-b improves natural killer (NK) cell activity.
-
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
12/7/2023
Phio Pharmaceuticals Corp. today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023.
-
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
6/2/2023
Phio Pharmaceuticals Corp. announced the closing of its previously announced registered direct offering of 233,646 shares of common stock, at a purchase price of $4.28 per share.
-
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
5/24/2023
Phio Pharmaceuticals Corp. today announced its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual.
-
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
5/18/2023
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer.
-
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
5/16/2023
Phio Pharmaceuticals Corp. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to proceed with a clinical trial of Phio's lead product candidate, PH-762.
-
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the quarter ended March 31, 2023 and provided a business update.
-
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/20/2023
Phio Pharmaceuticals Corp. announced the closing of its previously announced registered direct offering of 353,983 shares of common stock, at a purchase price of $5.65 per share, priced at-the-market under Nasdaq rules.
-
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
4/18/2023
Phio Pharmaceuticals Corp. today announced that in vivo data from a mouse model of colon cancer demonstrates target synergy-enhanced anti-tumor efficacy from a novel dual-targeting mouse PD-1 and CTLA-4 of an INTASYL coformulation.
-
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4/18/2023
Phio Pharmaceuticals Corp. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 353,983 of its shares of common stock at a purchase price of $5.65 per share in a registered direct offering priced at-the-market under Nasdaq rules.
-
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
4/17/2023
Phio Pharmaceuticals Corp. today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy ("abscopal effect").
-
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
3/22/2023
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the year ended December 31, 2022 and provided a business update.
-
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer
2/22/2023
Phio Pharmaceuticals Corp. today announced that Robert Bitterman has been appointed by the Board of Directors.
-
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements - February 13, 2023
2/13/2023
Phio Pharmaceuticals Corp. announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement.
-
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
2/10/2023
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that an independent Data Monitoring Committee (DMC) completed its prespecified review of interim safety data in the Company's Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.
-
Phio Pharmaceuticals Announces Reverse-January 25, 2023 Stock Split
1/25/2023
Phio Pharmaceuticals Corp. today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock.
-
Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco
1/6/2023
Phio Pharmaceuticals, a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th.
-
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
12/21/2022
Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762.
-
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
11/10/2022
Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology makes immune cells more effective in killing tumor cells, today announced the results of several studies of its INTASYL™ compounds.